Rexulti is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM ), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Rexulti is approved for the treatment of schizophrenia, and as an adjunctive treatment for major depressive disorder (MDD ). Although it failed Phase II clinical trials for ADHD , it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD ).
The most commonly observed adverse effects include: weight increase, akathisia, somnolence, tremor and nasopharyngitis. Neonates are at risk for extrapyramidal and/or withdrawal symptoms if exposed to an antipsychotic drug during the third trimester of development.